CCL4 Polyclonal Antibody, PeproTech®, Invitrogen™

Description

AA Sequence of recombinant protein: APMGSDPPTA CCFSYTARKL PHNFVVDYYE TSSLCSQPAV VFQTKRGKQV CADPSESWVQ EYVYDLELN. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human MIP-1beta (CCL4). Anti-Human MIP-1beta (CCL4)-specific antibody was purified by affinity chromatography employing an immobilized Human MIP-1beta (CCL4) matrix. Sandwich ELISA: To detect Human MIP-1beta (CCL4) by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human MIP-1beta (CCL4) (500-P38BBt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human MIP-1beta (CCL4). Western Blot: To detect Human MIP-1beta by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. When used in conjunction with compatible secondary reagents, the detection limit for Recombinant Human MIP-1beta is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

CCL4 (macrophage inflammatory protein 1-beta, MIP1B) belongs to the intercrine beta (chemokine CC) family. Functionally, CCL4 is involved in chemotactic and proinflammatory effects, and homeostasis. CCL4 is produced by macrophages upon stimulation by bacterial endotoxins. CCL4 recruits and stimulates various inflammatory cells at sites of inflammation. CCL4 is produced by lymphocytes, macrophages and dendritic cells. Both CCL4 and the related protein CCL3 participate in the host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells. While both CCL4 and CCL3 exert similar effects on monocytes, their effect on lymphocytes differ, with CCL4 selectively attracting CD4+ lymphocytes and CCL3 selectively attracting CD8+ lymphocytes. Additionally, both have been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. The processed form of CCL4 can induce down-modulation of surface expression of the chemokine receptor CCR5, thus inhibiting the CCR5-mediated entry of HIV-1 in T cells. CCL4 binds with high affinity to CCR5 receptors.